- Home
- AMSF vs EOLS Comparison
AMSF vs EOLS Comparison
Compare AMSF & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMSF
- EOLS
- Stock Information
- Founded
- AMSF 1985
- EOLS 2012
- Country
- AMSF United States
- EOLS United States
- Employees
- AMSF N/A
- EOLS N/A
- Industry
- AMSF Accident &Health Insurance
- EOLS Biotechnology: Pharmaceutical Preparations
- Sector
- AMSF Finance
- EOLS Health Care
- Exchange
- AMSF Nasdaq
- EOLS Nasdaq
- Market Cap
- AMSF 930.7M
- EOLS 1.1B
- IPO Year
- AMSF 2005
- EOLS 2018
- Fundamental
- Price
- AMSF $51.04
- EOLS $16.24
- Analyst Decision
- AMSF Buy
- EOLS Strong Buy
- Analyst Count
- AMSF 1
- EOLS 6
- Target Price
- AMSF $65.00
- EOLS $22.60
- AVG Volume (30 Days)
- AMSF 120.6K
- EOLS 566.7K
- Earning Date
- AMSF 10-23-2024
- EOLS 11-05-2024
- Dividend Yield
- AMSF 2.90%
- EOLS N/A
- EPS Growth
- AMSF N/A
- EOLS N/A
- EPS
- AMSF 2.97
- EOLS N/A
- Revenue
- AMSF $309,130,000.00
- EOLS $237,260,000.00
- Revenue This Year
- AMSF N/A
- EOLS $34.62
- Revenue Next Year
- AMSF N/A
- EOLS $33.33
- P/E Ratio
- AMSF $17.16
- EOLS N/A
- Revenue Growth
- AMSF 1.25
- EOLS 40.71
- 52 Week Low
- AMSF $41.97
- EOLS $7.44
- 52 Week High
- AMSF $54.80
- EOLS $17.82
- Technical
- Relative Strength Index (RSI)
- AMSF 64.16
- EOLS 48.44
- Support Level
- AMSF $47.56
- EOLS $16.37
- Resistance Level
- AMSF $51.56
- EOLS $17.57
- Average True Range (ATR)
- AMSF 0.91
- EOLS 0.71
- MACD
- AMSF 0.29
- EOLS -0.10
- Stochastic Oscillator
- AMSF 85.09
- EOLS 13.66
About AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance to employers engaged in hazardous industries, mainly construction, trucking, manufacturing, oil and gas, and agriculture. The company generates a majority of its revenue in the form of premiums.
About EOLS Evolus Inc.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.